Cargando…

Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis

Liver receptor homolog-1 (LRH-1, Nr5a2) is an orphan nuclear receptor mainly expressed in tissues of endodermal origin, where its physiological role has been extensively studied. LRH-1 has been implicated in liver cell differentiation and proliferation, as well as glucose, lipid, and bile acid metab...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwaderer, Juliane, Phan, Truong San, Glöckner, Astrid, Delp, Johannes, Leist, Marcel, Brunner, Thomas, Delgado, M. Eugenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048823/
https://www.ncbi.nlm.nih.gov/pubmed/32111818
http://dx.doi.org/10.1038/s41419-020-2348-9
_version_ 1783502342743654400
author Schwaderer, Juliane
Phan, Truong San
Glöckner, Astrid
Delp, Johannes
Leist, Marcel
Brunner, Thomas
Delgado, M. Eugenia
author_facet Schwaderer, Juliane
Phan, Truong San
Glöckner, Astrid
Delp, Johannes
Leist, Marcel
Brunner, Thomas
Delgado, M. Eugenia
author_sort Schwaderer, Juliane
collection PubMed
description Liver receptor homolog-1 (LRH-1, Nr5a2) is an orphan nuclear receptor mainly expressed in tissues of endodermal origin, where its physiological role has been extensively studied. LRH-1 has been implicated in liver cell differentiation and proliferation, as well as glucose, lipid, and bile acid metabolism. In addition, increasing evidence highlights its role in immunoregulatory processes via glucocorticoid synthesis in the intestinal epithelium. Although the direct function of LRH-1 in immune cells is fairly elucidated, a role of LRH-1 in the regulation of macrophage differentiation has been recently reported. In this study, we aimed to investigate the role of LRH-1 in the regulation of pro-inflammatory cytokine production in macrophages. Our data demonstrate that pharmacological inhibition, along with LRH-1 knockdown, significantly reduced the lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines in the macrophage line RAW 264.7 cells, as well as in primary murine macrophages. This inhibitory effect was found to be independent of defects of LRH-1-regulated cell proliferation or toxic effects of the LRH-1 inhibitors. In contrast, LRH-1 inhibition reduced the mitochondrial ATP production and metabolism of macrophages through downregulation of the LRH-1 targets glucokinase and glutminase-2, and thus impairing the LPS-induced macrophage activation. Interestingly, in vivo pharmacological inhibition of LRH-1 also resulted in reduced tumor necrosis factor (TNF) production and associated decreased liver damage in a macrophage- and TNF-dependent mouse model of hepatitis. Noteworthy, despite hepatocytes expressing high levels of LRH-1, pharmacological inhibition of LRH-1 per se did not cause any obvious liver damage. Therefore, this study proposes LRH-1 as an emerging therapeutic target in the treatment of inflammatory disorders, especially where macrophages and cytokines critically decide the extent of inflammation.
format Online
Article
Text
id pubmed-7048823
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70488232020-03-04 Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis Schwaderer, Juliane Phan, Truong San Glöckner, Astrid Delp, Johannes Leist, Marcel Brunner, Thomas Delgado, M. Eugenia Cell Death Dis Article Liver receptor homolog-1 (LRH-1, Nr5a2) is an orphan nuclear receptor mainly expressed in tissues of endodermal origin, where its physiological role has been extensively studied. LRH-1 has been implicated in liver cell differentiation and proliferation, as well as glucose, lipid, and bile acid metabolism. In addition, increasing evidence highlights its role in immunoregulatory processes via glucocorticoid synthesis in the intestinal epithelium. Although the direct function of LRH-1 in immune cells is fairly elucidated, a role of LRH-1 in the regulation of macrophage differentiation has been recently reported. In this study, we aimed to investigate the role of LRH-1 in the regulation of pro-inflammatory cytokine production in macrophages. Our data demonstrate that pharmacological inhibition, along with LRH-1 knockdown, significantly reduced the lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines in the macrophage line RAW 264.7 cells, as well as in primary murine macrophages. This inhibitory effect was found to be independent of defects of LRH-1-regulated cell proliferation or toxic effects of the LRH-1 inhibitors. In contrast, LRH-1 inhibition reduced the mitochondrial ATP production and metabolism of macrophages through downregulation of the LRH-1 targets glucokinase and glutminase-2, and thus impairing the LPS-induced macrophage activation. Interestingly, in vivo pharmacological inhibition of LRH-1 also resulted in reduced tumor necrosis factor (TNF) production and associated decreased liver damage in a macrophage- and TNF-dependent mouse model of hepatitis. Noteworthy, despite hepatocytes expressing high levels of LRH-1, pharmacological inhibition of LRH-1 per se did not cause any obvious liver damage. Therefore, this study proposes LRH-1 as an emerging therapeutic target in the treatment of inflammatory disorders, especially where macrophages and cytokines critically decide the extent of inflammation. Nature Publishing Group UK 2020-02-28 /pmc/articles/PMC7048823/ /pubmed/32111818 http://dx.doi.org/10.1038/s41419-020-2348-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Schwaderer, Juliane
Phan, Truong San
Glöckner, Astrid
Delp, Johannes
Leist, Marcel
Brunner, Thomas
Delgado, M. Eugenia
Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
title Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
title_full Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
title_fullStr Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
title_full_unstemmed Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
title_short Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
title_sort pharmacological lrh-1/nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048823/
https://www.ncbi.nlm.nih.gov/pubmed/32111818
http://dx.doi.org/10.1038/s41419-020-2348-9
work_keys_str_mv AT schwadererjuliane pharmacologicallrh1nr5a2inhibitionlimitsproinflammatorycytokineproductioninmacrophagesandassociatedexperimentalhepatitis
AT phantruongsan pharmacologicallrh1nr5a2inhibitionlimitsproinflammatorycytokineproductioninmacrophagesandassociatedexperimentalhepatitis
AT glocknerastrid pharmacologicallrh1nr5a2inhibitionlimitsproinflammatorycytokineproductioninmacrophagesandassociatedexperimentalhepatitis
AT delpjohannes pharmacologicallrh1nr5a2inhibitionlimitsproinflammatorycytokineproductioninmacrophagesandassociatedexperimentalhepatitis
AT leistmarcel pharmacologicallrh1nr5a2inhibitionlimitsproinflammatorycytokineproductioninmacrophagesandassociatedexperimentalhepatitis
AT brunnerthomas pharmacologicallrh1nr5a2inhibitionlimitsproinflammatorycytokineproductioninmacrophagesandassociatedexperimentalhepatitis
AT delgadomeugenia pharmacologicallrh1nr5a2inhibitionlimitsproinflammatorycytokineproductioninmacrophagesandassociatedexperimentalhepatitis